Resiquimod (R848) | TLR7/8 Agonist | MedChemExpress
Article Reference
Systemic administration of a TLR7 agonist attenuates regulatory T cells by dendritic cell modification and overcomes resistance to PD-L1 blockade therapy | Oncotarget
Ascendis files IND for sustained-release, anti-cancer TLR drug | Fierce Pharma
Recent Advances in the Discovery and Delivery of TLR7/8 Agonists as Vaccine Adjuvants | ImmunoHorizons
Resiquimod - an overview | ScienceDirect Topics
Resiquimod (R-848) | ≥99%(HPLC) | Selleck | TLR agonist
High Capacity poly(2-oxazoline) formulation of TLR 7/8 agonist extends survival in a chemo-insensitive, metastatic model of Lung Adenocarcinoma | bioRxiv
Systemic administration of low-dose resiquimod induces activation of... | Download Scientific Diagram
Resiquimod - an overview | ScienceDirect Topics
Resiquimod - an overview | ScienceDirect Topics
Resiquimod is an effective therapy for early-stage CTCL. Changes from... | Download Scientific Diagram
Mesoporous Silica Nanoparticles as pH-Responsive Carrier for the Immune-Activating Drug Resiquimod Enhance the Local Immune Response in Mice | ACS Nano
The novel synthetic immune response modifier R-848 (Resiquimod) shifts human allergen-specific CD4+ TH2 lymphocytes into IFN-γ–producing cells - Journal of Allergy and Clinical Immunology
Topical Resiquimod Protects against Visceral Infection with Leishmania infantum chagasi in Mice | Clinical and Vaccine Immunology
Frontiers | Cancer Vaccines, Adjuvants, and Delivery Systems
Topical Resiquimod Protects against Visceral Infection with Leishmania infantum chagasi in Mice | Clinical and Vaccine Immunology
Pharmaceutics | Free Full-Text | A Squalene-Based Nanoemulsion for Therapeutic Delivery of Resiquimod | HTML
High-capacity poly(2-oxazoline) formulation of TLR 7/8 agonist extends survival in a chemo-insensitive, metastatic model of lung adenocarcinoma | Science Advances
Oral resiquimod in chronic HCV infection: Safety and efficacy in 2 placebo- controlled, double-blind phase IIa studies - Journal of Hepatology
The TLR7/8 agonist R848 remodels tumor and host responses to promote survival in pancreatic cancer | Nature Communications
Lipid conjugation of TLR7 agonist Resiquimod ensures co-delivery with the liposomal Cationic Adjuvant Formulation 01 (CAF01) but does not enhance immunopotentiation compared to non-conjugated Resiquimod+CAF01 - ScienceDirect
Frontiers | Anti-tumor Activity of Toll-Like Receptor 7 Agonists
Resiquimod (R848) | TLR7/8 Agonist | MedChemExpress
